Intrexon Corporation creates biologically based products such as gene and cell therapies, microbial bioproduction, regenerative medicine and biologically engineered solutions.

According to the law firm press release, the lawsuit alleges Intrexon issued false and misleading financial statements to investors. On April 21, 2016, Spotlight Research issued a report revealing that Intrexon’s revenues were overstated through transactions with related parties. The lawsuit claims that when this adverse information entered the market, the price of Intrexon stock dropped, damaging investors.

On July 25, 2016, the Court issued an Order appointing Lead Plaintiff and approving Lead Counsel. Lead Plaintiff filed an amended Complaint on September 22.

On February 24, 2017, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiffs were given 30 days to file an amended Complaint. Plaintiffs did not file, thus this case was dismissed with prejudice on April 26.